Floatz logo

MAT2A-IN-9

Peritoneal Mesothelioma

IDEAYA BiosciencesSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

18 Active assets in the Peritoneal Mesothelioma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 2BB
MITOMYCIN C
National Cancer Institute (NCI)
Phase 2B
Sodium Thiosulfate
National Cancer Institute (NCI)
Phase 2B
Nivolumab
TCR2 Therapeutics
Phase 2B
Eloxatin
Hospices Civils de Lyon
Phase 2B

View all 20 →

Same molecule, other indications

MAT2A-IN-9 is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
57 / 100
View asset →
MTAP-null Solid TumorsDormant
CCC
Indicative ·
52 / 100
View asset →
lung adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →